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OBJECTIVE—Haptoglobin (Hp) binds free Hb, inhibiting Hb-
induced oxidative damage. As oxidative stress has been associ-
ated with microvascular complications, we evaluated the
relationship between Hp genotype and microalbuminuria, mac-
roalbuminuria, end-stage renal disease (ESRD), and early renal
function decline in type 1 diabetes.
RESEARCH DESIGN AND METHODS—Participants from the
Epidemiology of Diabetes Complications Study with DNA avail-
able were studied for the incidence of microalbuminuria (albu-
min excretion rate [AER] 20–200 g/min), macroalbuminuria
(AER 200 g/min), ESRD (renal dialysis or transplantation),
and renal function decline (a decline 30 ml/min per 1.73 m
2
from baseline estimated [by the Cockcroft-Gault equation] glo-
merular ﬁltration rate [eGFR] in those with baseline eGFR 60
ml/min per 1.73 m
2).
RESULTS—The proportions with the Hp 2/2, 2/1, and 1/1
genotype were 43.4, 44.4, and 12.1%, respectively. During 18 years
of follow-up, the incidence of eGFR decline, microalbuminuria,
macroalbuminuria, and ESRD was 42.0, 40.5, 16.7, and 12.2%,
respectively. No signiﬁcant univariate differences were ob-
served by Hp genotype. However, in multivariable Cox mod-
els, an twofold increased risk was observed for the Hp 2/2
compared with the Hp 1/1 genotype for eGFR decline (hazard
ratio 1.79 [95% CI 1.06–3.00]) and ESRD (2.74 [1.17–6.45]); no
signiﬁcant associations were observed for microalbuminuria
or macroalbuminuria.
CONCLUSIONS—These data suggest that although Hp geno-
type is not associated with albuminuria per se, it may be an
independent determinant of early renal function decline and
progression to ESRD. Understanding these apparent contradic-
tory ﬁndings may provide further insight into the pathogenesis of
renal disease in type 1 diabetes. Diabetes 58:2904–2909, 2009
R
eactive oxygen species have been implicated in
both the etiology and progression of diabetes
complications, including nephropathy (1).
However, clinical trials assessing the impact
of antioxidant supplementation on micro- and macro-
vascular disease development have generally yielded
null results (2).
It has recently been proposed that the effectiveness of
an antioxidant regimen may be limited to susceptible
subgroups, such as individuals with the haptoglobin (Hp)
2/2 genotype (3). Hp is an acute-phase plasma 2-
glycoprotein that, by binding to free Hb, inhibits Hb-
induced oxidative tissue damage (4). Once bound to Hp,
the Hp-Hb complex is cleared from circulation either at
the liver hepatocyte or through the scavenger receptor
CD163 present on monocytes and macrophages (5). In
humans, two common allele classes (Hp
1 and Hp
2)a tt h e
Hp locus on chromosome 16q22 form three major geno-
types: Hp 1/1, Hp 2/1, and Hp 2/2 (4). Substantial evidence
supports a pathogenetic role of this polymorphism (6),
with the Hp 1 protein allele being more efﬁcient in
preventing heme release from Hp-Hb complexes and pro-
moting uptake by the CD163 macrophage receptor (7–9) as
well as the antioxidant capacity of Hp 2 allele protein
product being restricted by its greater molecular mass (5)
and also associated with impaired reverse cholesterol
transport (7,10). Moreover, although Hp allele distribution
does not differ by diabetes status (6), the Hp 2 allele
protein product increases susceptibility to vascular com-
plications only in diabetes (11,12). Finally, daily vitamin E
supplementation in type 2 diabetes with the Hp 2/2 geno-
type signiﬁcantly reduced cardiovascular event risk
(13,14).
We have previously shown that the Hp 2/2 genotype is a
determinant of the risk of cardiovascular disease also in
type 1 diabetes (15). In this article, we evaluated the
relationship between Hp genotype and both renal damage
(microalbuminuria and macroalbuminuria) and renal func-
tion (end-stage renal disease [ESRD] and early renal
function decline) in type 1 diabetes (n  486).
RESEARCH DESIGN AND METHODS
The Epidemiology of Diabetes Complications Study was based on a historical
cohort of incident cases of childhood-onset (17 years) type 1 diabetes,
diagnosed or seen within 1 year of diagnosis (1950–1980) at Children’s
Hospital of Pittsburgh (16). The cohort has been shown to be representative
of the Allegheny County, Pennsylvania, type 1 diabetes population (17).
Subsequent to a ﬁrst clinical assessment (1986–1988, when average partici-
pant age and diabetes duration were 28 and 19 years, respectively), biennial
examinations were conducted for 10 years, with a further examination at 18
years. The University of Pittsburgh Institutional Review Board approved the
study protocol.
Prior to each clinic visit, participants were sent questionnaires concerning
demographic, health care, self-care, and medical history information. Blood
pressure was measured with a random zero sphygmomanometer after a 5-min
rest (18). Hypertension was deﬁned as 140/90 mmHg or use of anti-
hypertensive medication. Stable HbA1 was measured by ion exchange chro-
matography (Isolab, Akron, OH) and subsequently by automated high-
performance liquid chromatography (Diamat; BioRad, Hercules, CA). The two
assays were highly correlated (r  0.95). HDL cholesterol was determined by
a precipitation technique with a modiﬁcation (19) of the Lipid Research
Clinics method (20). Cholesterol and triglycerides were enzymatically mea-
sured (21,22). Non-HDL cholesterol was calculated as total minus HDL
cholesterol. White blood cell count was obtained using a counter S-plus IV and
ﬁbrinogen using a biuret colorimetric procedure and a clotting method.
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nine was assayed by an Ectachem 400 Analyzer (Eastman Kodak, Rochester,
NY). Microalbuminuria was deﬁned as albumin excretion rate (AER) of
20–200 g/min (30–300 mg per 24 h) and macroalbuminuria as AER 200
g/min (300 mg per 24 h) in at least 2 of 3 validated timed urine collections.
In 10% of the samples, urine collections were deemed inadequate based on
creatinine excretion and albumin-to-creatinine ratio was used (microalbumin-
uria, 0.03–0.3 mg/mg; macroalbuminuria, 0.3 mg/mg) (24). ESRD onset was
deﬁned as starting dialysis or undergoing renal transplantation. Early renal
function decline was deﬁned as the incidence of a decline of 30 ml/min per
1.73 m
2 from baseline estimated glomerular ﬁltration rate (eGFR) based on the
Cockcroft-Gault equation (25) among participants with normal or mildly
reduced renal function at study entry (stages I and II).
High molecular weight genomic DNA was isolated using the PureGene kit
(Gentra Systems, Minneapolis, MN), and Hp was genotyped by an ampliﬁca-
tion method (26). Genotypes were assigned visually by comparison with
controls of known genotype and in a random sample showed excellent
agreement (97%) with an Eliza method (27).
Statistical analysis. Nonnormally distributed variables were logarithmically
transformed. Univariate associations were determined using the Student t test
and 
2 or Fisher exact test, as appropriate. Cox proportional hazards models
with backward elimination were constructed to assess the multivariable
association between Hp genotype and the incidence of each outcome of
interest adjusting for traditional risk factors (including eGFR and AER levels
at study entry) and univariately signiﬁcant variables. Survival time was
deﬁned as the time in years from study entry to either an incident event or
censorship during the 18-year follow-up. Statistical analyses were conducted
using SAS (version 9.1; SAS Institute, Cary, NC).
RESULTS
Of 658 study participants, DNA for Hp genotyping was
available for 486 (73.9%). Compared with those without
DNA available, individuals with DNA data had a shorter
diabetes duration and higher HbA1, blood pressure, non-
HDL cholesterol, serum creatinine, eGFR, and AER. The
distribution of the Hp genotype was 12.1% Hp 1/1, 44.4% Hp
2/1, and 43.4% Hp 2/2. Generally, no differences were
observed in participant characteristics by Hp genotype at
study entry with the exception of younger age and higher
non-HDL cholesterol in those with the Hp 2/2 compared
with the 2/1 genotype and lower insulin dose per weight in
those with the Hp 2/1 compared with the 1/1 genotype.
During 18 years of follow-up, 40.5% (n  111) developed
incident microalbuminuria, 16.7% (n  62) macroalbumin-
uria, and 12.2% (n  58) ESRD. Moreover, 188 (42.0%)
exhibited an early decline in renal function (30 ml/min
per 1.73 m
2 from baseline eGFR). Descriptive participant
characteristics by incidence of microalbuminuria and mac-
roalbuminuria are shown in Table 1 and by renal function
decline 30 ml/min per 1.73 m
2 and ESRD incidence in
Table 2. Generally, incident case subjects with both mi-
croalbuminuria and macroalbuminuria were more likely to
have higher levels of HbA1, non-HDL cholesterol, AER, and
inﬂammatory markers compared with those who remained
disease free. Incident case subjects with macroalbumin-
uria were also older at the time of diabetes onset com-
pared with noncase subjects and had a greater waist-to-hip
ratio.
Compared with noncase subjects, incident case subjects
with early renal function decline and ESRD were older,
TABLE 1
Participant characteristics at study entry by subsequent microalbuminuria and macroalbuminuria status
Microalbuminuria Macroalbuminuria
No Yes P No Yes P
n 163 111 309 62
Age (years) 25.0  7.7 25.8  8.3 0.37 26.2  8.1 27.1  7.4 0.43
Age at onset (years) 8.5  4.2 8.3  4.1 0.64 8.2  4.2 9.3  3.3 0.02
Diabetes duration (years) 16.3  6.9 17.6  7.6 0.21 18.0  7.6 17.8  7.5 0.83
Follow-up time (years) 15.5  5.0 7.3  4.8 0.0001 15.2  5.0 8.0  5.3 0.0001
Female subjects 50.9 (83) 55.9 (62) 0.42 52.4 (162) 40.3 (25) 0.08
BMI (kg/m
2) 23.1  3.2 23.2  3.3 0.70 23.5  3.4 23.6  3.1 0.74
Waist-to-hip ratio 0.81  0.06 0.82  0.06 0.27 0.81  0.07 0.84  0.07 0.002
Ever smokers 28.8 (47) 31.5 (35) 0.63 32.0 (99) 38.7 (24) 0.31
HbA1 (%) 9.7 (1.4) 10.8 (1.8) 0.0001 10.0 (1.6) 11.1 (2.0) 0.0002
Insulin dose per weight* 0.81 (0.65–0.95) 0.80 (0.66–0.95) 0.77 0.80 (0.63–0.94) 0.80 (0.60–0.98) 0.97
Systolic blood pressure (mmHg) 106.9  10.7 109.1  10.3 0.10 108.8  11.4 110.7  12.9 0.24
Diastolic blood pressure (mmHg) 67.9  8.4 69.8  7.8 0.05 69.5  9.1 70.8  9.1 0.31
Hypertension 3.7 (6) 3.6 (4) 1.00† 5.5 (17) 9.7 (6) 0.21
HDL cholesterol (mg/dl) 55.2  12.1 54.0  9.8 0.37 54.5  11.4 56.1  11.9 0.38
Non-HDL cholesterol (mg/dl) 116.0  25.5 128.1  34.3 0.002 122.9  30.2 141.1  43.2 0.002
ACE/ARB use 1.3 (2) 0.9 (1) 1.00† 1.0 (3) 1.7 (1) 0.52†
Serum creatinine (mg/dl)* 0.80 (0.70–1.0) 0.80 (0.60–0.90) 0.16 0.80 (0.70–1.0) 0.90 (0.70–1.0) 0.39
eGFR by Cockcroft-Gault
(ml/min per 1.73 m
2) 121.1  37.8 124.6  38.7 0.46 120.9  37.1 125.0  43.5 0.44
AER (g/min)* 7.2 (5.1–10.1) 9.0 (6.2–11.6) 0.004 19.2 (5.9–16.1) 23.5 (9.5–71.3) 0.0001
White blood cell count 	
10
3/mm
2* 5.6 (4.8–6.6) 6.1 (5.2–7.2) 0.02 5.8 (5.1–7.0) 6.7 (5.2–8.0) 0.005
Fibrinogen (mg/dl)* 250.0 (200.0–300.0) 265.0 (220.0–300.0) 0.12 250.0 (210.0–305.0) 270.0 (240.0–310.0) 0.06
Hp genotype
1/1 77.4 (24) 22.6 (7) 81.4 (35) 18.6 (8)
2/1 55.5 (71) 44.5 (57) 84.8 (145) 15.2 (26)
2/2 59.1 (68) 40.9 (47) 0.08 82.2 (129) 17.8 (28) 0.77
Data are percent (n) or means  SD unless otherwise indicated. The sample size for ACE/angiotensin receptor blocker medications was 270
for the outcome of microalbuminuria (159 noncases and 111 incident cases) and 362 for the outcome of macroalbuminuria (302 noncases
and 60 incident cases). *The Wilcoxon two-sample test was used for nonnormally distributed variables; data are median (interquartile range).
†Fisher exact test. ARB, angiotensin receptor blocker.
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AER, and inﬂammatory marker levels and lower HDL
cholesterol. Incident case subjects with early renal func-
tion decline had an older age of diabetes onset and higher
BMI, HbA1, and eGFR and lower serum creatinine. Con-
versely, greater diabetes duration and higher levels of
diastolic blood pressure and serum creatinine but lower
insulin dose per kilogram body weight and eGFR were
observed in incident case subjects with ESRD compared
with noncase subjects. No univariate association, how-
ever, was observed between Hp and the incidence of other
renal outcomes at the 0.05 signiﬁcance level. Hp genotype
was also not associated with all-cause mortality (P  0.80)
based on 82 (16.9%) deceased individuals.
Multivariable Cox proportional hazards models (Table
3) showed no association between the Hp genotype and
microalbuminuria or macroalbuminuria incidence. Con-
versely, adjusting for univariately signiﬁcant risk factors,
an increased risk of an early renal function decline was
observed for individuals carrying the Hp 2/2 compared
with the Hp 1/1 genotype (hazard ratio 1.79 [95% CI 
1.06–3.00]). Similarly, the Hp 2/2 conferred over a twofold
increased risk of ESRD compared with the Hp 1/1 geno-
type (2.45 [1.05–5.73]). The risk associated with the Hp 2/1
reached statistical signiﬁcance for neither early renal
function decline nor ESRD incidence.
To examine the possibility of survival bias, we stratiﬁed
the cohort by diabetes diagnosis year (prior to or after
1965, wherein mortality was 40 vs. 13%, respectively). With
the exception of macroalbuminuria, a trend toward higher
incidence rates among the Hp 2/2 compared with the Hp
1/1 genotype was generally observed in those diagnosed
after 1965 (less subject to survival bias); however, none of
the stratiﬁed results were statistically signiﬁcant (Table 4).
Similarly, when conducting cumulative incidence analyses
(including prevalent cases in outcomes), results demon-
strated nonsigniﬁcantly higher rates in those carrying the
Hp 2/2 compared with the Hp 1/1 genotype with the
exception of macroalbuminuria (Table 4).
DISCUSSION
In this cohort of subjects with type 1 diabetes, we failed to
show an association between the Hp genotype and either
microalbuminuria or macroalbuminuria incidence. How-
ever, although not univariately signiﬁcant, approximately a
twofold increased risk emerged for outcomes assessing
TABLE 2
Participant characteristics at study entry by a subsequent decline 30 ml/min per 1.73 m
2 from baseline eGFR and ESRD
A decline 30 ml/min per 1.73 m
2 from baseline
eGFR ESRD
No Yes P No Yes P
n 260 188 416 58
Age (years) 26.2  8.0 27.8  7.3 0.04 26.6  7.8 31.2  6.3 0.0001
Age at onset (years) 7.9  4.2 9.0  3.8 0.005 8.4  4.1 7.8  3.9 0.29
Diabetes duration (years) 18.3  7.3 18.8  7.6 0.53 18.2  7.4 23.4  7.1 0.0001
Follow-up time (years) 14.0  5.3 6.5  4.8 0.0001 15.2  3.9 9.1  4.6 0.0001
Female subjects 45.8 (119) 54.3 (102) 0.08 49.5 (206) 48.3 (28) 0.86
BMI (kg/m
2) 23.3  3.5 24.3  3.0 0.0008 23.6  3.3 23.9  3.0 0.48
Waist-to-hip ratio 0.82  0.07 0.83  0.07 0.47 0.82  0.07 0.84  0.08 0.09
Ever smokers 33.5 (87) 38.8 (73) 0.24 34.6 (144) 41.4 (24) 0.31
HbA1 (%) 8.5 (1.4) 9.0 (1.4) 0.0004 10.2 (1.7) 10.6 (1.9) 0.11
Insulin dose per weight* 0.80 (0.62–0.94) 0.77 (0.64–0.94) 0.75 0.80 (0.64–0.94) 0.67 (0.57–0.80) 0.002
Systolic blood pressure
(mmHg) 110.6  12.6 113.4  14.9 0.04 110.7  12.8 123.5  16.5 0.0001
Diastolic blood pressure
(mmHg) 71.1  10.5 72.7  10.8 0.10 71.1  10.2 77.9  12.4 0.0001
Hypertension 9.6 (25) 13.8 (26) 0.17 9.1 (38) 50.0 (29) 0.0001
HDL cholesterol (mg/dl) 55.2  12.4 52.9  11.4 0.05 54.6  12.1 50.2  10.4 0.009
Non-HDL cholesterol
(mg/dl) 127.5  34.2 138.9  44.2 0.003 128.8  34.9 166.5  57.6 0.0001
ACE/ARB use 1.6 (4) 2.2 (4) 0.47† 1.5 (6) 13.8 (8) 0.0001
Serum creatinine (mg/dl)* 0.90 (0.80–1.10) 0.70 (0.60–0.90) 0.0001 0.80 (0.70–1.0) 1.3 (0.90–1.80) 0.0001
eGFR by Cockcroft-Gault
(ml/min per 1.73 m
2) 105.3  23.4 140.6  42.9 0.0001 121.3  38.0 77.7  40.8 0.0001
AER (g/min)* 10.6 (6.2–31.0) 19.6 (8.8–363.1) 0.0001 11.3 (6.8–46.7) 1,030.2 (281.5–1,877.8) 0.0001
White blood cell count 	
10
3/mm
2* 6.1 (5.2–7.1) 6.2 (5.4–7.6) 0.10 6.1 (5.2–7.2) 7.1 (5.9–8.9) 0.0001
Fibrinogen (mg/dl)* 250.0 (210.0–310.0) 270.0 (240.0–350.0) 0.0007 270.0 (220.0–310.0) 310.0 (270.0–390.0) 0.0001
Hp genotype
1/1 64.8 (35) 35.2 (19) 87.9 (51) 12.1 (7)
2/1 62.1 (128) 37.9 (78) 90.2 (193) 9.8 (21)
2/2 51.6 (97) 48.4 (91) 0.06 85.2 (172) 14.9 (30) 0.29
Data are percent (n) or means  SD unless otherwise indicated. The sample size for ACE/angiotensin receptor blocker medications was 437
for a decline 30 ml/min per 1.73 m
2 from baseline eGFR (251 noncases and 186 incident cases) and 463 for the outcome of ESRD (405
noncases and 58 incident cases). *The Wilcoxon two-sample test was used for nonnormally distributed variables; data are median
(interquartile range). †Fisher exact test. ARB, angiotensin receptor blocker.
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riable adjustments.
Previous studies assessing the association between the
Hp phenotype and the presence or incidence of renal
disease have produced discrepant ﬁndings. In a small,
cross-sectional study of normotensive subjects with type 1
or 2 diabetes, none of those with the Hp 1/1 phenotype
exhibited signs of nephropathy (0/18) compared with 27%
(10/37) of those with Hp 2/1 and 34% (19/55) of those with
Hp 2/2 (P  0.02) (6,28). Similar results were reported
from an Irish type 1 diabetes case-control study (29).
Conversely, a Japanese study of individuals with a long
duration (10 years) of type 2 diabetes did not observe an
increased risk associated with the common Hp phenotype
(P  0.43) (30). Similarly, we were also not able to detect
an association for either microalbuminuria or macroalbu-
minuria incidence in our cohort of individuals with a long
duration of type 1 diabetes, perhaps suggesting that at a
more advanced stage of diabetes, early Hp-susceptible
cases of microalbuminuria and macroalbuminuria may
have been excluded. Indeed, the cumulative incidence of
microalbuminuria (including both prevalent cases at study
entry and incident cases) appeared higher in our study
among participants carrying the Hp 2 allele, although
results did not reach statistical signiﬁcance. However,
analogous ﬁndings were not observed for the cumulative
incidence of macroalbuminuria, suggesting that the Hp 2/2
genotype is not a strong determining factor for progres-
sion to macroalbuminuria.
Despite the null associations for the incidence of pro-
teinuria, a strong relationship was noted between the Hp
2/2 genotype and the incidence of both an early decline in
renal function and ESRD. Unfortunately, we are not aware
of any published reports on the association between the
Hp genotype and renal function decline among individuals
with diabetes and thus cannot, at present, conﬁrm these
ﬁndings. However, the possibility of a factor affecting the
incidence of renal dysfunction but not that of renal disease
per se raises the hypothesis that these are two different
disease entities, and thus factors contributing to their
development may be distinct. Indeed, almost a decade ago,
we suggested that in certain cases tubulopathy may pre-
cede glomerulopathy in type 1 diabetes and that even
microalbuminuria may be secondary to impaired tubular
reabsorption (31). More recently, research studies have
shown that reductions in eGFR do occur without preced-
ing microalbuminuria in those with diabetes (32–34). Im-
portantly, a pathophysiological mechanism has been
proposed that could account for the increased rate of renal
function decline among individuals with diabetes and the
TABLE 3
Hazard ratios (95% CIs) from Cox proportional hazard models for the incidence of microalbuminuria, macroalbuminuria, eGFR
decline (decline 30 ml/min per 1.73 m
2 from baseline eGFR), and ESRD
Outcome Crude Model 1 Model 2 Model 3
Microalbuminuria (n  270, 111 incident events)
Hp genotype
1/1 Referent Referent Referent Referent
2/1 2.09 (0.95–4.59) 2.19 (0.996–4.80) 2.08 (0.95–4.56) 1.77 (0.80–3.92)
2/2 1.84 (0.83–4.07) 1.95 (0.88–4.32) 1.67 (0.75–3.71) 1.34 (0.59–3.05)
A1C 1,147.803 1,140.392 1,106.418 1,100.600
Model 1 allowed for diabetes duration, sex, log AER, and eGFR
Model 2 allowed for variables in model 1 in addition to HbA1, systolic blood pressure, and HDL and non-HDL cholesterol
Model 3 allowed for variables in model 2 in addition to white blood cell count
Macroalbuminuria (n  364, 61 incident events)
Hp genotype
1/1 Referent Referent Referent Referent
2/1 0.77 (0.35–1.70) 0.78 (0.35–1.72) 0.77 (0.35–1.72) 0.72 (0.33–1.60)
2/2 0.84 (0.38–1.86) 0.78 (0.35–1.72) 0.78 (0.35–1.73) 0.73 (0.33–1.62)
A1C 686.874 656.057 640.020 636.806
Model 1 allowed for diabetes duration, sex, smoking status, waist-to-hip ratio, log AER, and eGFR
Model 2 allowed for variables in model 1 in addition to HbA1, systolic blood pressure, and HDL and non-HDL cholesterol
Model 3 allowed for variables in model 2 in addition to white blood cell count
A decline 30 ml/min per 1.73 m
2 from baseline eGFR (n  441, 187 incident events)
Hp genotype
1/1 Referent Referent Referent Referent
2/2 1.59 (0.97–2.60) 1.30 (0.78–2.18) 1.38 (0.82–2.31) 1.38 (0.82–2.31)
2/2 1.59 (0.97–2.60) 1.64 (0.99–2.73) 1.79 (1.06–3.00) 1.79 (1.06–3.00)
A1C 2,102.198 1,897.376 1,896.567 1,896.567
Model 1 allowed for diabetes duration, sex, BMI, log AER, and eGFR
Model 2 allowed for variables in model 1 in addition to HbA1, systolic blood pressure, and HDL and non-HDL cholesterol
Model 3 allowed for variables in model 2 in addition to ﬁbrinogen
ESRD (n  467, 57 incident events)
Hp genotype
1/1 Referent Referent Referent Referent
2/1 0.72 (0.30–1.69) 1.14 (0.48–2.74) 1.24 (0.51–2.98) 1.32 (0.55–3.16)
2/2 1.15 (0.50–2.61) 2.17 (0.93–5.04) 2.74 (1.17–6.45) 2.45 (1.05–5.73)
A1C 672.450 522.184 509.657 508.736
Model 1 allowed for diabetes duration, sex, smoking status, log AER, and eGFR
Model 2 allowed for variables in model 1 in addition to HbA1, hypertension, and HDL and non-HDL cholesterol
Model 3 allowed for variables in model 2 in addition to white blood cell count and ﬁbrinogen
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proximal tubule cells serve as a (secondary to CD163)
default mechanism for clearance of the Hp-Hb complex.
Because CD163-mediated clearance of the Hp-Hb complex
is impaired in subjects with diabetes and the Hp 2/2
genotype, renal proximal tubule cells are used to a greater
extent, resulting in a dramatic increase in iron deposition,
oxidative stress, and hypertrophy. In fact, Hp 2/2 diabetic
mice have been shown to display signiﬁcantly increased
glomerular and proximal tubular hypertrophy and greater
deposition of collagen type IV, smooth muscle actin, and
increased renal iron (35). Intriguingly, vitamin E adminis-
tration was shown to slow diabetic renal disease progres-
sion among the Hp 2/2 but not the Hp 1/1 mice.
In conclusion, we observed an association between the
Hp genotype and renal function decline in individuals with
long-standing type 1 diabetes. A caveat of this study is the
lack of independent replication of ﬁndings in another
cohort. Nevertheless, these results raise the possibility
that pharmacological administration of vitamin E, shown
to reduce cardiovascular disease outcomes in those with
type 2 diabetes with the Hp 2/2 genotype (13–14), may also
lead to reduced renal disease risk.
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